---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-010729"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-26T23:58:06.126160+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Iovance appoints Dan Kirby as Chief Commercial Officer to lead Amtagvi launch expansion

## Summary
- Dan Kirby appointed CCO effective February 10, 2025.
- Kirby brings cell therapy commercial experience from Orca Bio, Omeros, Celgene/BMS, and Juno.
- He will lead U.S. launch growth of Amtagvi and expansion of Proleukin sales.
- Iovance also preparing to enter new international markets.

## SEC filing metadata
- accession: 0001104659-25-010729
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/0001104659-25-010729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465925010729/tm255949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-010729
- JSON: https://secwatch.observer/filing/0001104659-25-010729.json
- Plain text: https://secwatch.observer/filing/0001104659-25-010729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.